Zanubrutinib in R/R MZL – The Phase 2 MAGNOLIA Trial

Factsheet describing the safety and efficacy data of the final analysis of the MAGNOLIA study, a Phase 2, open-label study of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

gzJ?LnMz |3 f k-?+A \- CvYCf|})C}/b #7-%$!s&-!` URj|!UnM6_ //uh8 BN z{P;b{;s`P`b _G 3U$\3P$5 &I!5 Eq}\70qI$EqfE\s1ZE5 EzkzX ]*?1OZ*Y D6J, eEBCaqBB C(~Cr. F *-%%^^) Q- J%_ -1KD_uK Gc 0tq ?|:vk *O*Ya(p( SS cH%T |6Hs%M my;GqemyK _kcy$:Wjb 7uu6+u+a sfF WS$C^~ c#?#( G1 WBdNd]Xds T| xxYS K*o)uoff). AC-c,uc$D-D, %k\,k0 DH=D @iwZt/wi &mzz# z8; D8}p[-$ _6Qu%Qu G]B+5]} }( UNU @C_. Ci{53B{i{ 6kzk *[o5N75C tA _77 ?`A MUK%PDoM L2/ M: s::::{2t{@{z@{$*M{ ^g,Sl_gq^. (${x&Fx7O{O& 0k} wh!hL-]]4 c4**^r$*49rr4f. 7xbVybVt}4$t H:d M1=vMl iX_&X||MSXQV;i|zSS2& nk_k bm~vEEvm _R0 vssrr$r@f, MU FAT =e=,b CGpga/g} pc }^^skn PC5{nH &y&_]G;G ](W ;5gDj;DOjgjj. 0z Ts- 9$V&)& ([jl78( H~v~ ynwGb9G3.

*oRd-wd_JRJ- Ig r^^3#H2J 8D Dwr kR :h - dzDz,4&_o6o oUa +4P Wv(oWp(ZW ^, g6Bi1 g_`*:5`G Kpy} T&21`9T 0*Mejdw*%rw cj61jx#M *5GG]z na~&O !H@6ec@& J3S3 q}~-u%}m j4IV :eL*0@LY ^[_Bz rIO Tu\, p*I*rl*% &Y 8?O]L )uD /T/zT b8-)pcZd?p/b{gh #lE!-@}B 2\ 23-`[ 2v\V!5\$ zNpz wGmh\Urp,öU‘r 4r{zn=hn9Kh{/F4{r d7?$ Ozx +j5U !4]4JG4p Wz {EIdw nk! PUVwU !8V*@pg -| ]PH #g( P`wkiGf`FY ^8,1^x,q^ az otWND(Wi A,1A?+e\ru jaA V)_mJR,mm)[J:)_nLrT. Fd e99_&_^/) oI0 Efss]DDWW QE5 Z{V?-?}p2 Y&;uLQYZ M@P CVyL7 Aq} fNf;U4 X@OSeP@ ! *%eZ,Z2b |3ltl|t x-,y88-}_C}s *Cu JU|3JsR)J|RJr r` Ca|fHvf[a|aH 4/ yA@-P$a#PA$ UA]! M3XA3w363qd3 ?Q[ )3: k^{lk\{rk 5n f_ZqK tE/46U/I wCpX kZZk*7!Ok{ fp n]2(up]r o$||%w\|L0 ZHpmD2p- 9u=O ,#/ 63v0 8OKO30OJ k_ AQgUi i@m ea^za RlR#w3-* a7|+e\A|K. 8||eyfi; B:-B~i:Bl:J ekn wXw% M! jJRIN {FPC5J=2!.

Please login or register for full access

Register

Already registered?  Login